Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Tetrahydrocyclopenta[c]pyrrole derivative, preparation method and medical applications thereof

A compound and cycloalkyl technology, applied in the field of tetrahydrocyclopentadieno[c]pyrrole derivatives, can solve problems such as the influence of administration time, the slow onset of acid breakthrough at night, and instability

Inactive Publication Date: 2016-03-02
JIANGSU CAREFREE PHARM CO LTD +2
View PDF4 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Such as: the influence of administration time on drug efficacy; slow onset of acid breakthrough at night; instability under acidic conditions (need to be formulated into intestinal preparations); dependence on CYP450 enzymes (resulting in significant individual differences), etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tetrahydrocyclopenta[c]pyrrole derivative, preparation method and medical applications thereof
  • Tetrahydrocyclopenta[c]pyrrole derivative, preparation method and medical applications thereof
  • Tetrahydrocyclopenta[c]pyrrole derivative, preparation method and medical applications thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0065] Embodiment 1: the preparation of compound 1

[0066]

[0067] 1) Preparation of 5,6-dihydrocyclopenta[c]pyrrol-4(2H)-one (compound B)

[0068] At 0-5°C, a mixed solution of compound A (2.1g, 25.64mmol), p-methylsulfonylmethylisonitrile (5g, 25.64mmol), diethyl ether (20mL) and DMSO (20mL) was added dropwise to NaH (1.64g, 41mmol, 1.6eq), ether (15mL) solution. After the dropwise addition, the temperature was naturally raised to room temperature, and the reaction was stirred for 2 hours. .LC-MS detected that the reaction of the raw materials was complete, adding pure water (20mL) to the phase reaction system to quench the reaction, stirring for 15min, and extracting with diethyl ether (15mLx3) and ethyl acetate (15mLx3) respectively. The combined organic phases were dried, concentrated, and passed through a column (P:E=1:1) to obtain compound B (1.67 g, yield: 53.87%) as a yellow solid. HPLC: 85%; MS (ESI) m / z: [M+H] + =122.4;

[0069] 2) Preparation of 1-b...

Embodiment 2

[0078] Embodiment 2: the preparation of compound 2

[0079] Referring to the similar method of compound 1, 26 mg of compound 2 yellow oil was obtained. 1 H-NMR (400MHz, CDCl 3 )δ:8.71(d,1H),8.54(d,1H),7.60(d,1H),7.37(m,5H),7.11(m,2H),3.64(m,1H),2.55(t,2H ), 1.99(m,1H), 1.81(m,1H), 1.50(m,5H)ppm.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a class of new tetrahydrocyclopenta[c]pyrrole derivatives represented by a general formula (I) and a preparation method thereof, a pharmaceutical composition containing the derivative, and uses of the tetrahydrocyclopenta[c]pyrrole derivative as the treatment agent, particularly the gastric acid secretion inhibitor and the potassium ion competitive acid blocker (P-CABs). Each substituent in the general formula (I) is defined in the specification. The general formula (I) is defined in the specification.

Description

technical field [0001] The present invention relates to a new class of tetrahydrocyclopentadieno[c]pyrrole derivatives, a process for their preparation, pharmaceutical combinations containing the derivatives and their use as therapeutic agents, especially as gastric acid secretion inhibitors and potassium ion competitive agents. Use of acid blockers (P-CABs). Background technique [0002] Since 1988, proton pump inhibitors represented by omeprazole have been widely used clinically to treat peptic ulcer, reflux esophagitis and Zoller-Ellison syndrome by inhibiting gastric acid secretion. Long-term clinical application has found that existing proton pump inhibitors still have limitations in terms of pharmacokinetics and pharmacodynamics. Such as: the effect of administration time on drug efficacy; slow onset of acid breakthrough at night; instability under acidic conditions (need to be formulated into intestinal preparations); dependence on CYP450 enzymes (resulting in signif...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D401/12C07D401/14C07D409/12C07D405/12C07D209/52A61K31/403A61K31/4439A61K31/444A61K31/4709A61P1/04A61P1/00A61P1/14A61P29/00A61P35/00A61P31/04
Inventor 秦引林金秋
Owner JIANGSU CAREFREE PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com